Adolor Regains Rights to Entereg(R) (alvimopan) for OBD

EXTON, Pa.--(Business Wire)--
Adolor Corporation (Nasdaq: ADLR) announced today that
GlaxoSmithKline (GSK) has returned to Adolor worldwide rights related
to Entereg(R) (alvimopan) for chronic opioid bowel dysfunction (OBD).
GSK is retaining rights to Entereg for postoperative ileus (POI), and
the companies will continue to collaborate on the development and
commercialization of Entereg for POI in the United States.

Adolor announced in July 2008 that the U. S. Food and Drug
Administration (FDA) lifted the clinical hold on the OBD
Investigational New Drug Application.

"There is a large, unmet need for treatment options for the many
patients who suffer with chronic OBD," said Michael R. Dougherty,
president and chief executive officer of Adolor. "Adolor maintains a
portfolio of development candidates that may potentially serve this
patient population, including Entereg, our Combination Product
Program, and additional earlier stage compounds. We intend now to
explore discussions with potential partners regarding this portfolio,
and to submit to the FDA for review a protocol for an additional study
of Entereg in OBD under a Special Protocol Assessment."

Mr. Dougherty continued, "We value our relationship with GSK for
Entereg in POI a great deal and are pleased with the early progress of
our efforts under the E.A.S.E.(TM) Program. We will continue to work
closely with GSK in implementing this Program, and in making this
important new product available to bowel resection patients and
surgical teams."

GSK also returned to Adolor rights related to Entereg for
irritable bowel syndrome (IBS) and non-opioid induced forms of
constipation or bowel dysfunction. There have been no active
development programs for these indications.

About Adolor Corporation

Adolor Corporation (Nasdaq: ADLR) is a biopharmaceutical company
specializing in the discovery, development and commercialization of
novel prescription pain management products. By applying its knowledge
and expertise in pain management, along with ingenuity, Adolor is
seeking to make a positive difference for patients, caregivers and the
medical community. For more information, visit www.adolor.com.

Adolor Forward-Looking Statements

This release, and oral statements made with respect to information
contained in this release, may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those which express
plan, anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact.
These statements are based upon management's current expectations and
are subject to risks and uncertainties, known and unknown, which could
cause actual results and developments to differ materially from those
expressed or implied in such statements. Such known risks and
uncertainties relate to, among other factors: the risk that ENTEREG
may not be developed for OBD; the risk that future studies if
conducted with ENTEREG in OBD may not show efficacy or safety; the
risk that ENTEREG may not be a commercial success in POI; the
uncertainty of market acceptance of ENTEREG in POI, including
acceptance by hospitals, physicians, payors or the medical community;
the risk that the Risk Evaluation and Mitigation Strategy or REMS,
including the registration of hospitals could materially adversely
affect the commercial prospects for ENTEREG or negatively impact the
uptake of ENTEREG, the risks associated with government regulations
relating to marketing and selling pharmaceutical products; the risk of
product liability claims; the risks of reliance on third party
manufacturers; the risk of competitive products; the risk that ENTEREG
may not be approved in OBD or any indication other than the FDA
approved indication in bowel resection surgery; the risk that filing
targets for regulatory submissions are not met; the risk that the
results of other clinical trials of Adolor's drug products and drug
product candidates, including ENTEREG, are not positive or do not
support safety or efficacy; the costs, delays and uncertainties
inherent in scientific research, drug development, clinical trials and
the regulatory approval process; the changing regulatory environment;
risks associated with intellectual property protection for Adolor's
products and third party intellectual property; Adolor's history of
operating losses since inception and its need for additional funds to
operate its business; Adolor's reliance on its collaborators,
including GSK, in connection with the development and
commercialization of ENTEREG; market acceptance of Adolor's products,
if regulatory approval is achieved; competition; and securities
litigation.

Further information about these and other relevant risks and
uncertainties may be found in Adolor's Reports on Form 8-K, 10-Q and
10-K filed with the U.S. Securities and Exchange Commission. Adolor
urges you to carefully review and consider the disclosures found in
its filings which are available in the SEC EDGAR database at
http://www.sec.gov and from Adolor at http://www.adolor.com. Given the
uncertainties affecting pharmaceutical companies in the development
stage, you are cautioned not to place undue reliance on any such
forward-looking statements, any of which may turn out to be wrong due
to inaccurate assumptions, unknown risks, uncertainties or other
factors. Adolor undertakes no obligation to (and expressly disclaims
any such obligation to) publicly update or revise the statements made
herein or the risk factors that may relate thereto whether as a result
of new information, future events, or otherwise.

This press release is available on the website
http://www.adolor.com.

Adolor Corporation
Lizanne Wentz, 484-595-1500
Corporate Communications
or
Sam Brown Inc. (media)
Mike Beyer, 773-463-4211

Copyright Business Wire 2008